Abstract P332: Impact of Empagliflozin on Anthropometry and Markers of Visceral Adiposity in Patients With Type 2 Diabetes: Effects by Age, Sex, And Degree of Abdominal Obesity
Introduction: Empagliflozin (EMPA) improves glycemia and reduces weight and visceral adiposity in patients with type 2 diabetes mellitus (T2DM). Heterogeneity of effects of EMPA on adiposity by age, sex, and degree of abdominal obesity are unknown.
Hypothesis: We assessed whether the effects of EMPA on weight and markers of visceral adiposity differ according to age, sex, and degree of abdominal obesity.
Methods: A pooled cohort of 2477 adults with T2DM from 4 randomized trials received EMPA (10/25mg daily) or placebo in addition to background therapy for 24 weeks. Changes in weight, waist circumference (WC), index of central obesity (ICO, WC/height), and visceral adiposity index (WC/39.68 + 1.88 x BMI x TG/1.03 x 1.31/HDL, males; WC/36.58 + 1.89 x BMI x TG/0.81 x 1.52/HDL, females) were assessed between baseline and week 24. Treatment effects stratified by age, sex, and degree of abdominal obesity (defined by WC) were compared with placebo using adjusted means by ANCOVA with interaction testing of treatment by subgroup.
Results: The cohort was 45.5% female; mean [SD] age: 55.6 [10.2] yrs; BMI: 28.7 [5.5] kg/m2. There were significantly greater reductions in weight and visceral adiposity markers among patients treated with EMPA compared with placebo across most groups stratified by age, sex, and degree of abdominal obesity (Table). Statistically significant interactions were seen by subgroups of age on weight (P-int=0.0281); WC (P-int=0.0098); and ICO (P-int=0.0101); and by abdominal obesity on weight (P-int=0.0024) suggesting that those with advanced age and abdominal obesity may achieve greater reductions in adiposity markers.
Conclusions: EMPA reduces weight and markers of visceral adiposity in patients with T2DM regardless of age, sex, or degree of abdominal obesity. Effects may be greater among older and more abdominally obese patients with potentially important implications for treatment of visceral adiposity-related T2DM in the future.
Author Disclosures: I.J. Neeland: None. D.K. McGuire: G. Consultant/Advisory Board; Modest; for trial of empagliflozin. R. Chilton: None. S. Crowe: A. Employment; Significant; Employee. S.S. Lund: A. Employment; Significant; Employee. H. Woerle: A. Employment; Significant; Employee. U.C. Broedl: A. Employment; Significant; Employee. O. Johansen: A. Employment; Significant; Employee.
- © 2015 by American Heart Association, Inc.